Interní Med. 2019; 21(4): 228-232 [Psychiatr. praxi 2019; 20(2): 60-63]

Inflammation as a part of the pathophysiology of depression and the possibility of its influence by polyunsaturated fatty acids

PharmDr. Bc. Hana Kotolová, Ph.D., PharmDr. Tomáš Hammer
Ústav humánní farmakologie a toxikologie, Farmaceutická fakulta, Veterinární a Farmaceutická univerzita Brno

Depression and other affective disorders are among the most prevalent mental disorders. The pathophysiology of this disease
is complex, and pro-inflammatory processes appear to play an important role in it. The article aims to summarize the existing
knowledge of the research of the interconnection of affective disorders and inflammation and their possible influence by recently
highly discussed polyunsaturated fatty acids.

Keywords: depression, inflammation, polyunsaturated fatty acids

Published: November 1, 2019  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kotolová H, Hammer T. Inflammation as a part of the pathophysiology of depression and the possibility of its influence by polyunsaturated fatty acids. Interní Med. 2019;21(4):228-232.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Moreno-Küstner B, Martin C, Pastor L, et al. Prevalence of psychotic disorders and its association with methodological issues. A systematic review and meta-analyses. PloS one, 2018, 13. 4. Go to original source...
    2. Depression and Other Common Mental Disorders: Global Health Estimates. Geneva: World Health Organization, 2017. Go to PubMed...
    3. Lee SH, et al. Is increased antidepressant exposure a contributory factor to the obesity pandemic?. Translational psychiatry, 2016, 6.3: e759. Go to original source... Go to PubMed...
    4. Whiteford HA, Degenhardt L, Rehm J, et al. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. The Lancet, 2013, 382.9904: 1575-1586. Go to original source... Go to PubMed...
    5. Baxter AJ, Scott KM, Ferrari AJ, et al. Challenging the myth of an "epidemic" of common mental disorders: trends in the global prevalence of anxiety and depression between 1990 and 2010. Depression and anxiety, 2014, 31.6: 506-516. Go to original source... Go to PubMed...
    6. Heald A, Pendlebury J, Anderson S, et al. Lifestyle factors and the metabolic syndrome in Schizophrenia: a cross-sectional study. Annals of General Psychiatry, 2017, 16.1: 12. Go to original source... Go to PubMed...
    7. Horska K, Kucerova, J, Suchy P, Kotolova H. Metabolic syndrome - dysregulation of adipose tissue endocrine function. Čes. Slov. Farm, 2014, 63.4, 152-159.
    8. Akbaraly TN, Kivimäki M, Brunner EJ, et al. Association between metabolic syndrome and depressive symptoms in middle-aged adults: results from the Whitehall II study. Diabetes care, 2009, 32.3: 499-504. Go to original source... Go to PubMed...
    9. Räikkönen K, Matthews KA, Kuller LH. Depressive symptoms and stressful life events predict metabolic syndrome among middle-aged women: a comparison of World Health Organization, Adult Treatment Panel III, and International Diabetes Foundation definitions. Diabetes care, 2007, 30.4: 872-877. Go to original source... Go to PubMed...
    10. Räikkönen K, Matthews KA, Kuller LH. The relationship between psychological risk attributes and the metabolic syndrome in healthy women: antecedent or consequence?. Metabolism-Clinical and Experimental, 2002, 51.12: 1573-1577. Go to original source... Go to PubMed...
    11. Heiskanen TH, Niskanen LK, Hintikka JJ, et al. Metabolic syndrome and depression: a cross-sectional analysis. The Journal of Clinical Psychiatry, 2006, 67.9: 1422-1427. Go to original source... Go to PubMed...
    12. Ventriglio A, Gentile A, Stella E, et al. Metabolic issues in patients affected by schizophrenia: clinical characteristics and medical management. Frontiers in Neuroscience, 2015, 9: 297. Go to original source... Go to PubMed...
    13. Grover S, Nebhinani N, Padmavati R, et al. Metabolic syndrome in antipsychotic na?ve patients with schizophrenia: pooled analysis of data from three Indian studies. Early Intervention in Psychiatry, 2015, 9.5: 357-362. Go to original source... Go to PubMed...
    14. Zuzarte P, Duong A, Figueira ML, et al. Current therapeutic approaches for targeting inflammation in depression and cardiovascular disease. Current Drug Metabolism, 2018, 19.8: 674-687. Go to original source... Go to PubMed...
    15. Pan A, Sun Q, Czernichow S, et al. Bidirectional association between depression and obesity in middle-aged and older women. International Journal Of Obesity, 2012, 595. Go to original source... Go to PubMed...
    16. Raboch J. Prevence v psychiatrii, Čas. Lék. čes. 2017; 156: 56-57
    17. Raboch J. Životní styl a afektivní poruchy, Čas. Lék. čes. 2017; 156: 74-80
    18. Jantaratnotai N, Mosikanon K, Lee Y, et al. The interface of depression and obesity. Obesity research & clinical practice, 2017, 11.1: 1-10. Go to original source... Go to PubMed...
    19. Kloiber S, Ising M, Reppermund S, et al. Overweight and obesity affect treatment response in major depression. Biological psychiatry, 2007, 62.4: 321-326. Go to original source... Go to PubMed...
    20. Wong ML, Licinio J. From monoamines to genomic targets: a paradigm shift for drug discovery in depression. Nature Reviews Drug Discovery, 2004, 3.2: 136. Go to original source... Go to PubMed...
    21. Manthey L, Leeds C, Giltay EJ, et al. Antidepressant use and salivary cortisol in depressive and anxiety disorders. European Neuropsychopharmacology, 2011, 21.9: 691-699. Go to original source... Go to PubMed...
    22. Loftis JM, Huckans M, Morasco BJ. Neuroimmune mechanisms of cytokine-induced depression: current theories and novel treatment strategies. Neurobiology of Disease, 2010, 37.3: 519-533. Go to original source... Go to PubMed...
    23. Hosák L, Kovařík A, Ustohal L, Látalová K. Duševní poruchy-epigenetické mechanizmy jejich vzniku a farmakologické léčby. Psychiatrie pro praxi, 2015, 16.2: 45-48.
    24. Miller AH, Raison CL. The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nature Reviews Immunology, 2016, 16.1: 22. Go to original source... Go to PubMed...
    25. Vancassel S, Capuron L, Castanon N. Brain kynurenine and BH4 pathways: relevance to the pathophysiology and treatment of inflammation-driven depressive symptoms. Frontiers in Neuroscience, 2018, 12: 499. Go to original source... Go to PubMed...
    26. Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosomatic Medicine, 2009, 71.2: 171-186. Go to original source... Go to PubMed...
    27. Dowlati Y, Herrmann N, Swardfager W, et al. A meta-analysis of cytokines in major depression. Biological Psychiatry, 2010, 67.5: 446-457. Go to original source... Go to PubMed...
    28. Dantzer R, O'Connor JC, Freund GG, et al. From inflammation to sickness and depression: when the immune system subjugates the brain. Nature Reviews Neuroscience, 2008, 9.1: 46. Go to original source... Go to PubMed...
    29. Syrovátka J. Deprese jako vedlejší účinek terapie interferonem alfa u nemocných s chronickou hepatitidou C, Psychiatr. pro Praxi, 2005; 1: 46
    30. Potměšil P. Je možné zvýšit účinnost antidepresiv přídatnou léčbou nesteroidními antirevmatiky?, Psychiatrie. 2017, 21(2), 87-92.
    31. Češková E. Nové možnosti léčby depresivní a schizofrenní poruchy Psychiatr. praxi 2018; 19(2): 53-56 Go to original source...
    32. Ouellet M, Emond V, Chen CT, et al. Diffusion of docosahexaenoic and eicosapentaenoic acids through the blood-brain barrier: an in situ cerebral perfusion study. Neurochemistry International, 2009, 55.7: 476-482. Go to original source... Go to PubMed...
    33. Lauritzen L, Brambilla P, Mazzocchi A, et al. DHA effects in brain development and function. Nutrients, 2016, 8.1: 6. Go to original source... Go to PubMed...
    34. Bourre JM, Pascal G, Durand G., et al. Alterations in the fatty acid composition of rat brain cells (neurons, astrocytes, and oligodendrocytes) and of subcellular fractions (myelin and synaptosomes) induced by a diet devoid of n3 fatty acids. Journal of Neurochemistry, 1984, 43.2: 342-348. Go to original source... Go to PubMed...
    35. Calder PC. Omega-3 fatty acids and inflammatory processes: from molecules to man. Biochemical Society Transactions, 2017, 45.5: 1105-1115. Go to original source... Go to PubMed...
    36. Young G, Conquer J. Omega-3 fatty acids and neuropsychiatric disorders. Reproduction Nutrition Development, 2005, 45.1: 1-28. Go to original source... Go to PubMed...
    37. British Nutrition Foundation (1999) N-3 Fatty Acids and Health, British Nutrition Foundation, London
    38. Simopoulos AP. The importance of the ratio of omega-6/omega-3 essential fatty acids. Biomedicine & Pharmacotherapy, 2002, 56.8: 365-379. Go to original source... Go to PubMed...
    39. Chiu CC, Huang SY, Su KP, et al. Polyunsaturated fatty acid deficit in patients with bipolar mania. European Neuropsychopharmacology, 2003, 13.2: 99-103. Go to original source... Go to PubMed...
    40. Ranjekar PK, Hinge A, Hegde MV, et al. Decreased antioxidant enzymes and membrane essential polyunsaturated fatty acids in schizophrenic and bipolar mood disorder patients. Psychiatry Research, 2003, 121.2: 109-122. Go to original source... Go to PubMed...
    41. Lin PY, Huang SY, Su KP. A meta-analytic review of polyunsaturated fatty acid compositions in patients with depression. Biological Psychiatry, 2010, 68.2: 140-147. Go to original source... Go to PubMed...
    42. Appleton KM, Rogers PJ, Ness AR. Is there a role for n-3 long-chain polyunsaturated fatty acids in the regulation of mood and behaviour? A review of the evidence to date from epidemiological studies, clinical studies and intervention trials. Nutrition Research Reviews, 2008, 21.1: 13-41. Go to original source... Go to PubMed...
    43. Frasure-Smith N, Lespérance F, Julien P. Major depression is associated with lower omega-3 fatty acid levels in patients with recent acute coronary syndromes. Biological Psychiatry, 2004, 55.9: 891-896. Go to original source... Go to PubMed...
    44. Sanchez-Villegas A, Henríquez P, Figueiras A, et al. Long chain omega-3 fatty acids intake, fish consumption and mental disorders in the SUN cohort study. European Journal of Nutrition, 2007, 46.6: 337-346. Go to original source... Go to PubMed...
    45. Noaghiul S, Hibbeln JR. Cross-national comparisons of seafood consumption and rates of bipolar disorders. American Journal of Psychiatry, 2003, 160.12: 2222-2227. Go to original source... Go to PubMed...
    46. Hibbeln JR. Fish consumption and major depression. Lancet, 1998, 351.9110: 1213. Go to original source... Go to PubMed...
    47. Hibbeln JR. Seafood consumption, the DHA content of mothers' milk and prevalence rates of postpartum depression: a cross-national, ecological analysis. Journal of Affective Disorders, 2002, 69.1-3: 15-29. Go to original source... Go to PubMed...
    48. Tanskanen A, Hibbeln JR, Tuomilehto J, et al. Fish consumption and depressive symptoms in the general population in Finland. Psychiatric Services, 2001, 52.4: 529-531. Go to original source... Go to PubMed...
    49. Balanzá-Martínez V, Fries GR, Colpo GD, et al. Therapeutic use of omega-3 fatty acids in bipolar disorder. Expert Review of Neurotherapeutics, 2011, 11.7: 1029-1047. Go to original source... Go to PubMed...
    50. Rutkofsky IH, Khan AS, Sahito S, et al. The psychoneuroimmunological role of Omega-3 polyunsaturated fatty acids in major depressive disorder and bipolar disorder. Adv Mind Body Med, 2017, 31.3: 8-16.
    51. Schefft C, Kilarski LL, Bschor T, et al. Efficacy of adding nutritional supplements in unipolar depression: A systematic review and meta-analysis. European Neuropsychopharmacology, 2017, 27.11: 1090-1109. Go to original source... Go to PubMed...
    52. Hallahan B, Ryan T, Hibbeln JR, et al. Efficacy of omega-3 highly unsaturated fatty acids in the treatment of depression. The British Journal of Psychiatry, 2016, 209.3: 192-201. Go to original source... Go to PubMed...
    53. Raboch J, Červený R. Deprese: doporučené diagnostické a terapeutické postupy pro všeobecné praktické lékaře 2018. Společnost všeobecného lékařství ČLS JEP, Praha 2018. Doporučené postupy pro praktické lékaře. ISBN 978-80-88280-05-7.
    54. Doporučené postupy psychiatrické péče 2018 [online]. Česká psychiatrická společnost, z.s, 2018. Dostupné z: https://postupy-pece.psychiatrie.cz
    55. Ravindran AV, Balneaves LG, Faulkner G, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 5. Complementary and alternative medicine treatments. The Canadian Journal of Psychiatry, 2016, 61.9: 576-587. Go to original source... Go to PubMed...
    56. Practice Guideline for the Treatment of Patients with Major Depressive Disorder (third ed.). American Psychiatric Association (APA), 2010.

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.